Please assess the completion status of the following clinical trial:

Trial Title: Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Phase I: Patients must have histologically confirmed relapsed or refractory Non-Hodgkin's lymphoma, Hodgkin's Disease or multiple myeloma (defined by World Health Organization (WHO) criteria).~Phase II: Patients must have histologically confirmed relapsed or refractory T-Cell Lymphoma (as defined by WHO criteria).~* Must have received first line chemotherapy. No upper limit for the number of prior therapies~* Evaluable Disease~* Age ≥18 years~* Eastern Cooperative Oncology Group (ECOG) performance status ≤2~* Patients must have adequate organ and marrow function as defined in the protocol~* Adequate Contraception~* Ability to understand and the willingness to sign a written informed consent document~* Inclusion Criteria for Multiple Myeloma patients specified in the protocol~Exclusion Criteria:~* Prior Therapy~  * Exposure to chemotherapy or radiotherapy within 2 weeks (6 weeks for nitrosureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 2 weeks earlier~ * Systemic steroids that have not been stabilized to the equivalent of ≤10 mg/day prednisone prior to the start of the study drugs~ * No other investigational agents are allowed~* Central nervous system metastases, including lymphomatous meningitis~* History of allergic reactions to Pralatrexate or Romidepsin~* Uncontrolled intercurrent illness~* Pregnant women~* Nursing women~* Current malignancy or history of a prior malignancy, as outlined in the protocol~* Patient known to be Human Immunodeficiency Virus (HIV)-positive~* Active Hepatitis A, Hepatitis B, or Hepatitis C infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phase I: Schedule A (Type: EXPERIMENTAL): Subjects will receive dose escalation of pralatrexate and romidepsin, receiving both infusions on days 1 and 8 of each 21 day cycle
- Phase I: Schedule B (Type: EXPERIMENTAL): Subjects will receive dose escalation of pralatrexate and romidepsin, receiving both infusions on days 1 and 15 of each 28 day cycle
- Phase II (Type: EXPERIMENTAL): Subjects will receive Pralatrexate 25 mg/m2 and Romidepsin 12 mg/m2 will be given intravenously once weekly on days 1 and 15 on a 28 day cycle

Based on this trial design, predict the completion outcome and termination type (if applicable).